Brought to you by 
Novartis applies Ligand's Captisol to its marketed melanoma drug trametinib
23 Jan 2018
Executive Summary
Ligand Pharmaceuticals Inc. will apply its Captisol drug formulation technology to Novartis AG's marketed melanoma drug trametinib to create an oral liquid version.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis applies Ligand's Captisol to its marketed melanoma drug trametinib
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice